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Phosphorus-31 metabolism of post-menopausal breast cancer studied in
vivo by magnetic resonance spectroscopy
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R.D. Rubens' & M.A. Richards'
'Imperial Cancer Research Fund Clinical Oncology Unit and 2Division ofRadiological Sciences, United Medical and Dental
Schools, Guy's Hospital, St. Thomas Street, London, SE] 9RT, UK.
Summary We have studied the metabolism of 31P-containing metabolites of post-menopausal breast cancers
in vivo using magnetic resonance spectroscopy (MRS) and a 5.5 cm surface coil. Spectra were acquired from 23
women (four previously treated and 19 previously untreated) with breast cancers more than 3.5 cm in
diameter. The spectra of the 19 previously untreated tumours had significantly higher phosphomonoester
(PME) 31P relative peak areas than the normal breasts of eight post-menopausal women (11.7% and 7.7%
respectively, P = 0.002). Although an increased PME relative peak area was characteristic of malignancy,
PME relative peak area is similarly raised in lactating breast and, therefore, not a specific feature of cancer.
An apparently lower nucleotide triphosphate (NTP) relative peak area in tumours than healthy post-
menopausal breast was secondary to the differences in PME relative peak area; contamination by signal from
chest wall muscle probably accounts for the ostensibly higher phosphocreatine (PCr) relative peak area of the
tumours. Spectroscopy was repeated following chemotherapy in six women. An increase in PCr relative peak
area was seen in all five patients who responded, but again this may represent increased contamination
secondary to changes in tumour size. A fall in PME relative peak area was noted in four responders, but also
one non-responder, so this finding may not be sufficiently specific to be of use clinically. Further studies are
needed to elucidate fully the role of MRS in breast cancer.
The potential of magnetic resonance spectroscopy (MRS) for
studying cellular metabolism in vivo was first demonstrated
when phosphorus (31P) spectra were acquired from animal
tissues by Hoult et al. (1974). Since then MRS has been
widely used to study chemical extracts from breast cancer
cells and cell lines in vitro and to investigate non-invasively
the metabolism of breast cancer in animal models. Studies of
extracts from human breast cancer cells (Merchant et al.,
1988, 1991) and intact cells studied in vitro (Degani et al.,
1986) suggest that cancers may have characteristic 3'P-MR
spectra which differ significantly from those of normal breast.
In cell lines it is also possible to predict response to treatment
(Evanochko et al., 1983) and even to identify drug-resistant
cells using 31P-MRS (Cohen et al., 1986; Evelhoch et al.,
1987). These studies would have important implications, both
for understanding of the metabolism of breast cancer and in
clinical practice, if confirmed in patients.
In vivo MR spectra from humans are generally less well
resolved than spectra acquired from animals in vivo and from
cell lines studied in vitro. Nevertheless, the 3'P-containing
metabolites which can be identified by human MRS in vivo
play a central role in the metabolism of both normal tissues
and tumours. The high-energy phophates phosphocreatine
(PCr) and nucleotide triphosphates (NTPs, predominantly
ATP) provide energy for cellular metabolism. By contrast,
inorganic phosphate (Pi) represents phosphate in its lowest
energy state; the position of the Pi peak is also an indicator
of intracellular pH (pHi). The phosphomonoester (PME)
peak encompasses the precursors of membrane synthesis,
including phosphorylethanolamine (PE) and phosphorylcho-
line (PC). The products of membrane breakdown, glycero-
phosphorylethanolamine (GPE) and glycerophosphorylcholine
(GPC), along with a significant contribution from phos-
pholipids (Smith et al., 1991; Lowry et al., 1992), are
components of the phosphodiester (PDE) peak at the field
strengths used for human studies in vivo.
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MR spectra obtained in vivo from women with breast
cancer have been reported by a number of groups (Ober-
haensli et al., 1986; Sijens et al., 1988; Glaholm et al., 1989;
Ng et al., 1989; Redmond et al., 1991, 1992; Smith et al.,
1991; Kalra et al., 1993). Since the majority of patients with
breast cancer are post-menopausal, it is particularly impor-
tant to define the role of 31P-MRS in this group of women.
The first aim of the current study was to characterise the
appearances of 31P spectra acquired at 1.5 tesla from un-
treated breast tumours in post-menopausal women. Secondly,
differences between malignant and normal tissue were studied
by comparing spectra with those acquired from healthy
breast in post-menopausal volunteers (Twelves et al., 1993).
Finally, the effect of treatment on 31P breast spectra was
studied in serial acquisitions prior to and following
chemotherapy.
Patients and methods
Patients
31P spectra were acquired from a total of 23 post-menopausal
women with breast cancer, 19 of whom had received no prior
treatment. A 5.5 cm surface coil was used for localisation.
Hence, only those women with tumours at least 3.5 cm in
diameter when measured clinically were considered for MRS,
as this usually resulted in the coil being separated from the
underlying chest wall by a distance equal to or greater than
its own diameter (see below). With the exception of one
woman, all patients had histological or cytological
confirmation of their breast cancer. Clinically, the remaining
woman had locally advanced breast cancer and subsequently
died of metastatic disease although initial cytology had failed
to identify malignant cells.
The following parameters were recorded: age, clinical
measurement of tumour size, tumour histology and grade,
steroid receptor status (where available). Since contamination
by signal from the underlying chest wall muscle is a potential
problem in breast spectroscopy (Twelves et al., 1993), the
distance between the coil and underlying chest wall muscle
(termed the CCW distance) was measured on MR images
whenever possible. In the six women from whom serial spectra
were obtained the response of the breast tumour to chemo-
therapy was assessed according to UICC criteria (Hayward et
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al., 1977) when the second spectrum was acquired and again
on completion of the course of treatment.
It was not possible to acquire spectra simultaneously from
the tumour and the contralateral breast. A second, separate
acquisition from the contralateral breast was considered
undesirable in these patients as we wanted to minimise the
additional demands placed on them. Therefore, the tumour
spectra were compared with the standard acquisitions from
healthy breast in post-menopausal women reported previ-
ously (Twelves et al., 1993). All women gave verbal consent
before undergoing MRS. The study was approved by the
Guy's Hospital ethics committee.
31P magnetic resonance spectroscopy
All examinations were performed at 1.5 T using a Gyroscan
S15 (Philips Medical Systems). In each case a purpose-built
5.5-cm-diameter surface coil (Ackerman et al., 1980) posi-
tioned over the tumour was used for localisation. The
majority of examinations were carried out with the patient
supine in order to optimise patient comfort. The four
patients scanned prone were positioned on the purpose-built
couch described previously (Twelves et al., 1993) and the
5.5 cm surface coil used as above. Where time allowed and
the patient agreed, proton images were acquired using the
body coil to transmit and to receive with a repetition time
(TR) of 415 ms and echotime (TE) of 20 ms. The following
standard 31P acquisition protocol was used: truncated Silver-
Hoult adiabatic half-passage (AHP) detection pulse with an
excitation bandwidth of approximately 800 Hz, sampling fre-
quency 2,000 Hz, 1,024 averages and a repetition time of 2 s.
Total acquisition time was 34 min.
Exponential line broadening of 5 Hz was applied to each
free induction delay (FID) before Fourier transformation.
Peak areas were measured by fitting a sum of Lorentzian
peaks to the frequency domain data with correction for
baseline distortion using a modification of the method de-
scribed by Lenkinski et al. (1989). Since the PCr peak
detected from normal breast is probably largely a con-
taminant from underlying chest wall muscle (Twelves et al.,
1993), the 31P relative peak areas were expressed in two ways.
Firstly, relative peak areas were calculated as a percentage of
the total 31P peak area of the spectrum. Secondly, they were
determined with PCr excluded from the denominator to
eliminate contamination by signal from muscle. The total
NTP relative peak area was defined as the sum of the y-, a-
and P-NTP peak areas (as well as other metabolites such as
NAD and FAD, which appear in this part of the spectrum),
again calculated by both methods.
The phosphodiester (PDE)/PME peak area ratio was cal-
culated. Although the PDE region is complex in spectra
collected in vivo at 1.5 T, it has been suggested that the
PDE/PME ratio may reflect membrane turnover (Ruiz-
Cabello & Cohen, 1992). The signal-to-noise ratio (SNR) of
each spectrum was expressed as the ratio of the P-NTP peak
height in the line-broadened spectrum to the root mean
square (RMS) noise in the Fourier transform of the
unfiltered time domain data.
Statistics
The Mann-Whitney test was used to compare patient char-
acteristics, 31P relative peak areas and peak area ratios. The
extent of the relationships between 31P relative peak areas
and other parameters was investigated using Pearson's cor-
relations; relationships with P<0.05 and r>0.5 were con-
sidered significant.
Results
The clinical characteristics of the 19 previously untreated,
post-menopausal women with breast cancer from whom a 3p
spectrum was acquired are shown in Table I. Serial acquisi-
tions prior to and following chemotherapy were collected
Table I Characteristics of previously untreated patients
No. of women 19
Median age 61.0 years
(range) (42-78)
Histology (grade)
Infiltrating ductal (III)
Infiltrating ductal (II)
Infiltrating lobular
Mixed
Unspecified
ER status
Positivea
Negative
Unknown
Prog R status
Positivea
Negative
Unknown
Median maximum
tumour diameter
(range)
Scan position
Supine
Prone
No. of MRS
examinations
Single
Serial
Median CCW
distanceb
(range)
Median 1-H
linewidth
(range)
a>10fmolll. bn =13.
9
1
3
4
7
6
6
4
11
4
10.0 cm
(3.7-15.0)
15
4
13
6
7.4 cm
(5.1-10.9)
0.42 ppm
(0.18-1.0)
from six women, four of whom had received prior treatment.
Steroid receptor status and histological subtype were un-
known for those women, in whom the diagnosis was made by
Bioptycut or at another unit.
Untreatedpost-menopausal breast tumours
The 31P spectrum obained from a breast cancer is shown in
Figure 1; the 31P relative peak areas of all 19 tumours are
shown in Figure 2. The Pi relative peak area was lower in the
seven oestrogen receptor (ER)-positive tumours than the six
ER-negative tumours, but this difference was of borderline
statistical significance (10.0% and 13.9% respectively;
P = 0.05) and must be treated with caution. There were no
statistically significant differences in the other relative peak
areas. Since only four tumours were progesterone receptor
(Prog R) positive, the effect of Prog R status on 31p spectra
could not be determined. There were no significant differ-
ences between the 31P relative peak areas of the nine infil-
trating ductal grade 3 tumours and the remaining ten
tumours. The heterogeneity of the precise histological diag-
nosis precluded further evaluation of the influence of tumour
grade on 31p spectra. The maximum tumour diameter did not
correlate with any 31P relative peak area.
Proton images were obtained from 13 of the 19 patients
and the CCW distance was measured. In these 13 women the
CCW distance was negatively correlated with PCr relative
peak area (r = - 0.57, P = 0.02; Figure 3a) and positively
correlated with PDE relative peak area (r = 0.58, P = 0.02;
Figure 3b). As muscle is known to have a high concentration
of PCr, these data suggest that the PCr and at least part of
the PDE apparently detected in the tumours may have
originated in underlying muscle and normal breast tissue
respectively. Other 31P relative peak areas did not correlate
with CCW distance.31P-MRS OF POST-MENOPAUSAL BREAST CANCER 1153
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Figure 1 3"P spectrum of tumour in a 67-year-old woman with a
13 cm, previously untreated, infiltrating ductal carcinoma and a
CCW distance of 6.7 cm.
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Figure 2 31P relative peak areas of breast tumours (triangles
represent 31P relative peak areas calculated with PCr excluded
from denominator).
Comparison with normalpost-menopausal breast
The 31P relative peak areas of the 19 untreated tumours were
compared with those of normal breast from the eight healthy
post-menopausal volunteers described previously. Those
spectra were acquired with the volunteer lying prone, rather
than supine as in the current study, on a purpose-built couch
with the breast hanging unsupported (Twelves et al., 1993).
There was no difference in the median age of the patients
with tumours and the volunteers (61 and 68 years respec-
tively; P>0.05). The median 1-H linewidth was, however,
significantly narrower for the tumours than the normal breast
(0.43 and 0.87 ppm respectively, P = 0.003) and similar to
that seen in normal premenopausal breast (Twelves et al.,
1993). The 31P relative peak areas of the tumours and normal
breast, with respect to total 31P peak area calculated both
with and without PCr, are compared in Table II.
Statistically significant differences were observed between
the tumours and normal breast, irrespective of whether PCr
was included in calculating the 31P relative peak areas. The
most striking feature, which was also apparent on visual
inspection, was that the tumours had a significantly larger
PME relative peak area than normal breast. This was re-
flected in the significantly lower PDE/PME peak area ratio
of the tumours relative to normal breast. The PCr relative
peak area was higher, but the NTP relative peak area lower,
in the tumours than in normal breast.
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Figure 3 a, Correlation between PCr relative peak area and
CCW distance (n = 13). b, Correlation between PDE relative
peak area and CCW distance (n = 13).
Table II Comparison of 31P relative peak areas from previously
untreated tumours and healthy breast (values in parentheses repre-
sent 31P relative peak areas calculated with PCr excluded from
denominator)
Median value
31P Tumours Normal breast P-value
parameter (n = 19) (n = 8) (Mann- Whitney)
PME area 11.7 7.7 0.002
(12.6) (8.1) (0.002)
Pi area 12.3 14.9 0.07
(13.0) (15.3) (0.12)
PDE area 31.5 27.1 0.50
(32.4) (27.6) (0.38)
PCr area 5.4 2.4 0.05
NTP area 37.9 46.0 0.002
(40.7) (46.6) (0.002)
PDE/PME 2.2 3.9 0.02
ratio
SNR 3.6 4.3 0.20
Figures in bold are statistically significant.
Since the 31P metabolites were expressed as relative peak
areas, a difference in relative peak areas between tumours
and normal breast may be either a primary metabolic feature
or secondary to variations in the other peak areas. The
difference in PME relative peak area between tumours and
normal breast remained significant when NTP was excluded
from the total 31P signal of the spectrum (P = 0.002). By
contrast, when the relative peak areas were calculated with
PME excluded from the denominator, the difference in NTP
relative peak area between the tumours and normal breast no
longer reached statistical significance (P = 0.07).
Effect ofchemotherapy
Spectra were acquired both before and after chemotherapy
from two women in the previously untreated group described
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above and a further four post-menopausal women who had
relapsed after tamoxifen (two women), radiotherapy and
tamoxifen (one woman) and radiotherapy, tamoxifen and
norethisterone acetate (one woman). In each case the first
spectrum was acquired within 24 h prior to the first cycle of
treatment and repeated 2-4 weeks following the start of
treatment; a further spectrum was acquired on completion of
the planned course of treatment in two women.
The treatment regimens and timing of repeat MRS, with
respect to day 1 as the date of initial chemotherapy, are
shown in Table III. The changes in peak areas are expressed
as the absolute change in the 31P relative peak areas between
the two MRS examinations. Changes in the peak area ratios
and response to treatment are also presented. At the time of
the 2-4 week repeat examination scan one woman had
achieved a minor response (MR, <50% reduction) to
chemotherapy; there was no change (NC) in the clinical
measurements of the remaining five women. The final re-
sponse to chemotherapy was a partial remission (PR) in three
women with a complete remission (CR), NC and progressive
disease (PD) each in one woman. It was not, therefore,
possible to make a statistical comparison of the spectral
characteristics of responders and non-responders. Never-
theless, the PME relative peak area had fallen by 2-4 weeks
in four patients; although three of these women ultimately
responded to chemotherapy, the fourth showed NC. A rise in
PME relative peak area was seen in the patient who subse-
quently had PD but also in the remaining responder. The
PME relative peak area had fallen further in the two women
studied again at the end of treatment, both of whom had
responded to chemotherapy.
All four patients who ultimately responded to chemo-
therapy had an increased PCr relative peak area on repeat
examination, whereas PCr relative peak area had fallen in the
only non-responder. No consistent pattern was noted in the
other 31P relative peak areas in relation to treatment. There
was a trend for SNR to be lower and 1-H linewidth to be
broader in all patients at the 2-4 week examination com-
pared with before treatment.
Discussion
Although 31P spectra have been acquired previously from
breast tumours, these studies have not fully defined the
appearances of breast carcinoma spectra and their relation-
ship to the spectra of normal breast. In particular, it is
important to define the clinical characteristics of the tumours
and to make comparisons with an appropriate group of
healthy volunteers. The first spectrum acquired in vivo from a
human breast cancer was from a post-menopausal woman,
but a spectrum could not be acquired from normal breast for
comparison (Oberhaensli et al., 1986). Other groups also
acquired spectra but did not make systematic comparisons
with normal breast (Glaholm et al., 1989; Ng et al., 1989;
Smith et al., 1991; Kalra et al., 1993). Sijens et al. (1988)
acquired spectra from breast tumours of four women who
were more than 50 years old, but the qualitative comparisons
they made were with normal breast from four younger,
presumably premenopausal, volunteers. In that study the
tumours showed increased PME, Pi and PDE peaks but
reduced PCr relative to normal breast.
Only Redmond et al. (1991) have previously compared
spectra of breast cancers from post-menopausal women with
those of healthy breast in post-menopausal volunteers; the
post-menopausal breast cancers had significantly higher a-
and y-NTP, but lower PCr, relative to the normal breast.
There were, however, important methodological differences
between that study and the current series. Redmond et al.
(1991) used surface coils with a large diameter in relation to
tumour and breast size, increasing the problem ofcontamina-
tion by surrounding normal breast and underlying chest wall
muscle. A 5.5-cm-diameter surface coil was used for localisa-
tion in the current study, and the problem of contamination
by signal from underlying tissues was minimised by limiting
the study to patients with tumours more than 3.5 cm in
diameter, so that in the 13 women from whom measurements
were made the distance between the chest wall muscle and
the coil was at least 5 cm. A further difference between the
study by Redmond et al. (1991) and the current report is that
we were able to increase the CCW distance by carrying out
examinations with the volunteers prone rather than supine.
Finally, the tumours examined by Redmond et al. (1991)
were substantially smaller than those described in the current
study.
Both normal and tumour 31P MR breast spectra show
considerable inter-subject variation. Nevertheless, the first
important finding in the current study is that the PME
relative peak area of breast carcinomas is significantly higher
than that of normal, post-menopausal breast. Previous
Table III Percentage change in 31P relative peak areas before and after chemotherapy (values in parentheses represent 31P relative peak areas
calculated with PCr excluded from denominator)
Day of Absolute change in 31P relative peak area Response
repeat Treatment and At repeat At end of
Patient exam schedule PME Pi PDE PCr NTP PDE/PME MRS treatment
1 14 Epirubicin -13.8 +4.5 +5.1 +1.2 +3.1 +4.98 NC NC
25 mg m-2 (-14.6) (4.9) (5.9) - (3.7) -
weekly
2 21 CMF +5.3 -1.6 -0.6 -5.8 +2.5 -0.83 NC PD
every 3 (4.9) (-2.4) (-2.7) - (3.7) -
weeks
3a .28 Epirubicin -0.7 0 -2.5 +1.9 +1.3 -0.05 NC PR
25 mg m-2 (-0.4) (+0.2) (-0.8) - (2.0) -
weekly
4 21 Epirubicin, -2.6 -3.8 +1.3 +2.7 +2.4 +2.3 NC PR
cyclophosphamide (-2.5) (-3.5) (2.3) - (3.9) -
and 5-FU
every 3 weeks
5b 21 Epirubicin -4.2 + 1.0 -1.1 +1.5 +0.6 +0.27 NC CR
25 mg m-2 (-4.1) (1.2) (-0.8) - (1.3) -
weekly
6 21 Doxorubicin +2.2 -5.4 -2.5 +4.7 -1.0 +4.48 MR PR
lO1 mg m-2 (4.0) (-4.2) (-0.8) - (-1.0) -
every 2 weeks
'PME fell by total of 14.6, and PCr rose by total of 12.9, at end of treatment. bPME fell by total of 15.0, and PCr rose by total of 16.9, at
end of treatment. cCyclophosphamide, methotrexate and 5-FU.31P-MRS OF POST-MENOPAUSAL BREAST CANCER 1155
clinical studies (Sijens et al., 1988; Ng et al., 1989) made the
same observation in small numbers of women, but Redmond
et al. (991) failed to detect such differences. Because of the
relatively poor resolution of human 3"P-NMR spectra, the
components of the PME peak cannot be identified in vivo.
With the improved resolution of spectra of perchloric acid
(PCA) extracts prepared from human breast cancer biopsy
specimens, PE, a precursor in the synthesis of membrane
phospholipids, has been identified as the major component of
the PME peak in human breast cancer (Merchant et al.,
1988; Smith et al., 1991; Lowry et al., 1992). In PCA extracts
the PE signal was increased in breast tumours compared with
normal breast (Merchant et al., 1988) and an increased PME
signal from human breast cancer cells studied in vitro has
been confirmed by Degani et al. (1986). A prominent PME
peak is also a feature of breast cancer cell lines studied in
vitro (Cohen et al., 1986) and of xenografts studied in vivo
(Sijens et al., 1988; Evelhoch et al., 1987).
The studies described above support the finding in the
current study that an increased PME relative peak area is a
feature of breast cancer. Recently, Kalra et al. (1993)
emphasised PME as a marker of proliferation by demon-
strating a relationship between the PME/NTP peak area
ratio and S-phase fraction in women with breast cancer.
However, the PME relative peak area of spectra acquired in
vivo from lactating breast is also significantly greater than
that of non-lactating premenopausal breast (Twelves et al.,
1993). Indeed, the PME relative peak areas of lactating
breast and cancers in post-menopausal women are similar
(16.8% and 12.8% respectively; P = 0.3). There are several
possible reasons why the PME signal should be increased
under these two distinct circumstances. Firstly, PME may
simply reflect the increased proportion of epithelial tissue,
either normal or malignant, relative to fat and connective
tissue in lactating breast or in the presence of a tumour.
Alternatively, the elevated PME relative peak area may be
due to increased membrane synthesis in hyperplastic or pro-
liferating breast tissue. It is clear, however, that while an
increased PME relative peak area is characteristic of malig-
nancy this is not a specific feature and cannot be considered
diagnostic of malignancy. The overlap between the PME
relative peak areas of healthy and malignant breast, and the
relatively low sensitivity of 3'P-MRS in vivo, emphasise that
attempts to use this technique to differentiate between nor-
mal and malignant breast tissue are unlikely to be success-
ful.
Other apparent differences were detected between the
tumours and healthy post-menopausal breast. The PCr
relative peak area was higher in the tumours than in normal
breast. This is in contrast to the findings in vivo of Sijens et
al. (1988) and Redmond et al. (1991), and of Merchant et al.
(1988), who studied human breast tumour extracts; all re-
ported less PCr in breast tumours than in normal breast.
However, the PCr relative peak area of healthy breast
(Twelves et al., 1993) and breast tumours is correlated with
the CCW distance. In the current study 15 of the 19 patients
were examined supine, whereas the spectra from healthy
post-menopausal breast were acquired with the volunteer
prone and the breast unsupported in order to reduce con-
tamination by signal from the underlying chest wall.
Therefore the apparently greater PCr signal from the
tumours may reflect a shorter CCW distance in patients with
tumours compared with those acting as healthy controls.
Although a small PCr peak has been detected in PCA ex-
tracts of human breast cancer biopsies (Merchant et al.,
1988; Lowry et al., 1992) and some breast cancer cell lines
(Cohen et al., 1986) it is likely that the main component of
the PCr detected from breast tumours in vivo is contamina-
tion from the underlying chest wall muscle. Conclusions
regarding the bioenergetics of breast tumours in vivo should
not, therefore, be drawn from the PCr peak area or PCr/Pi
peak area ratio.
Similarly, when expressed relative to the total 31P peak
area of the spectrum the NTP relative peak area was
significantly lower in the tumours than in normal breast.
Although this might indicate areas of ischaemia or enhanced
aerobic glycolysis within breast tumours, this difference was
no longer apparent when PME was excluded from total 31P
peak area. This indicates that these differences in NTP
relative peak area were largely, if not entirely, secondary to
alterations in the PME relative peak area and not a primary
metabolic feature of the tumours.
Changes in the PME peak have also been a feature of
human breast tumours studied in vivo from a total of ten
patients following radiotherapy (Sijens et al., 1988; Glaholm
et al., 1989), chemotherapy (Redmond et al., 1992) and
radiotherapy combined with chemotherapy (Ng et al., 1989).
Interestingly, all of the patients described previously had
responded to treatment so the specificity of changes in 31P
metabolites could not be evaluated. In the four women who
received chemotherapy alone, a variety of changes in peak
areas, including a fall in PME peak area ratio, were noted at
differing times following treatment (Redmond et al., 1992).
In the current study spectroscopy was repeated at around 3
weeks, when the second cycle of many chemotherapy regi-
mens is due but it is too early to evaluate response clinically.
These data have confirmed that a fall in PME relative peak
area is frequently seen in patients prior to changes in tumour
size measured clinically in women who respond to treatment.
However, one patient who later achieved a response did not
have an early fall in PME relative peak area, while the
patient with NC had shown a fall in PME relative peak area.
Although Redmond et al. (1992) described a rise in the
Pi/PME peak area ratio as characteristic of a response to
treatment, in the current study Pi/PME fell significantly in
one of the patients who responded. Changes in the PME
relative peak area are not, therefore, uniformly predictive of
response.
A frequent feature of animal MRS studies in vivo has been
an increase in the high-energy phosphates of tumours follow-
ing treatment. For example, Evanochko et al. (1983) de-
scribed an increase in the PCr peak and decrease in the Pi
peak from the 16/C mammary tumour following treatment
with doxorubicin. These changes preceded alterations in
tumour size. Sijens et al. (1988) described an increase in the
PCr peak from two human breast cancers studied in vivo
before and after radiotherapy. In the current study an in-
crease in the PCr relative peak area was seen in all five
patients who later responded but not in the patient who
failed to respond. The CCW distance did not differ signifi-
cantly between the serial spectroscopy studies. Nevertheless,
since the PCr signal probably originates largely in the chest
wall rather than the tumour or healthy breast, the rise in PCr
relative peak area may represent increased contamination as
a result of subtle changes in tumour size or composition. If
changes in PCr relative peak area do reflect altered tumour
size rather than metabolism, imaging techniques supplement-
ing clinical measurement are likely to be more useful at
present than MRS in monitoring early signs of response.
In conclusion, the current study has established that in
post-menopausal women there are significant differences
between the 31P-MR spectra of normal breast and car-
cinomas. Although the subjects were positioned differently
for the acquisitions from healthy breast and tumours, the
PME relative peak area of breast carcinomas was signifi-
cantly higher than that of normal breast. However, a high
PME relative peak area is also seen in healthy lactating
breast and is not a specific feature of malignancy. This has
important implications for the interpretation of the PME
peak, which is increased in many types of tumour. The
differences between tumours and normal breast with regard
to the NTP relative peak area are secondary to the altered
PME peak area, and variation in PCr is probably due to
contamination. Therefore, these features do not reflect
-differences in tumour bioenergetics. Similarly, although an
elevated PCr relative peak area was characteristic of an early
response to chemotherapy, this may reflect slight physical
rather than metabolic changes in the tumour. A fall in the
PME relative peak area is frequently indicative of a response
to chemotherapy, but at present this finding may not be1156 C.J. TWELVES et al.
sufficiently specific to be of use clinically. Further systematic
studies are required in well-defined groups of patients,
preferably using effective volume selection techniques such as
conformal image-selected in vivo spectroscopy (ISIS) (Sharp
& Leach, 1989) with absolute quantification of metabolites in
order to define fully the role of "P-MRS as both a research
tool and a clinical investigation in patients with breast
cancer.
References
ACKERMAN, J.H., GROVE, T.H., WONG, G.G., GADIAN, D.G. &
RADDA, G.K. (1980). Mapping of metabolites in whole animals
by 31P NMR using surface coils. Nature, 283, 167-170.
COHEN, J.S., LYON, R.C., CHEN, C., FAUSTINO, J., BATIST, G.,
SHOEMAKER, M., RUBALCABA, E. & COWAN, K.H. (1986).
Differences in phosphate metabolite levels in drug-sensitive and
-resistant human breast cancer cell lines determined by 31P
magnetic resonance. Cancer Res., 46, 4087-4090.
DEGANI, H., HOROWITZ, A. & ITZCHAK, Y. (1986). Breast tumours:
evaluation with P-31 MR spectroscopy. Radiology, 161,
53-56.
EVELHOCH, J.L., KELLER, N.A. & CORBETT, T.H. (1987). Response-
specific adriamycin sensitivity marker provided by in vivo 31P
nuclear magnetic resonance spectroscopy in murine mammary
adenocarcinoma. Cancer Res., 47, 3396-3401.
EVANOCHKO, W.T., NG, T.C., LILLY, M.B., LAWSON, A.J., CORBETT,
T.H., DURANT, J.R. & GLICKSON, J.D. (1983). In vivo 31P NMR
study of the metabolism of murine mammary 16/C adenocar-
cinoma and its response to chemotherapy, X-irradiation and
hyperthermia. Proc. Natl Acad. Sci. USA, 80, 334-338.
GLAHOLM, J., LEACH, M.O., COLLINS, D.J., MANSI, J., SHAR, J.C.,
MADDEN, A., SMITH, I.E. & MCCREADY, V.R. (1989). In vivo 31P
magnetic resonance spectroscopy for monitoring treatment re-
sponse in breast cancer. Lancet, i, 1326-1327.
HAYWARD, J.L., CARBONE, P.P., HEUSON, J.C., KUMAOKA, S.,
SEGALOFF, A. & RUBENS, R.D. (1977). Assessment of response
to therapy in advanced breast cancer. Eur. J. Cancer, 13,
89-94.
HOULT, D.I., BUSBY, S.J.W., GADIAN, D.G., RADDA, G.K.,
RICHARDS, R.E. & SEELEY, P.J. (1974). Observation of tissue
metabolites using 31-P nuclear magnetic resonance. Nature, 252,
285-287.
KALRA, R., WADE, K.E., HANDS, L., STYLES, P., CAMLEJOHN, R.,
GREENHALL, R., ADAMS, G.E., HARRIS, A.L. & RADDA, G.K.
(1993). Phosphomonoester is associated with proliferation in
human breast cancer: a 31P-MRS study. Br. J. Cancer, 67,
1145-1153.
LENKINSKI, R.E., ALLMAN, T., SCHEINER, J.D. & DEMING, S.N.
(1989). An automated iterative algorithm for the quantitative
analysis of in vivo spectra based on the simplex optimisation
method. Magn. Reson. Med., 10, 338-348.
LOWRY, M., PORTER, D.A., TWELVES, C.J., HEASLEY, P.E., SMITH,
M.A. & RICHARDS, M.A. (1992). Visibility of phospholipids in 31p
NMR spectra of human breast tumours in vivo. NMR Biomed., 5,
37-42.
MERCHANT, T.E., GIERKE, L.W., MENESES, P. & GLONEK, T.
(1988). 31P Magnetic resonance spectroscopic profiles of neoplas-
tic human breast tissues. Cancer Res., 48, 5112-5118.
MERCHANT, T.E., MENESES, P., GIERKE, L.W., DEN OTTER, W. &
GLONEK, T. (1991). 31P Magnetic resonance phospholipid profiles
of neoplastic human breast tissues. Br. J. Cancer, 63,
693-698.
NG, T.C., GRUNDFEST, S., VIJAYAKUMAR, S., BALDWIN, N.J.,
MAJORS, A.W., KARALIS, I., MEANEY, T.F., SHIN, K.H.,
THOMAS, F.J. & TUBBS, R. (1989). Therapeutic response of breast
carcinoma monitored by 31P MRS in situ. Magn. Reson. Med.,
10, 125-134.
OBERHAENSLI, R.D., BORE, J., RAMLING, R., HILTON-JONES, D.,
HANDS, L. & RADDA, G.K. (1986). Biochemical investigation of
human tumours in vivo with phosphorus-31 magnetic resonance
spectroscopy. Lancet, ii, 8-11.
REDMOND, O.M., STACK, J.P., O'CONNOR, N.G., CODD, M.B. &
ENNIS, J.T. (1991). In vivo phosphorus-31 magnetic resonance
spectroscopy of normal and pathological breast tissues. Br. J.
Radiol., 64, 210-216.
REDMOND, O.M., STACK, J.P., O'CONNOR, N.G., CARNEY, D.N.,
DERVAN, P.A., HURSON, B.J. & ENNIS, J.T. (1992). 31P MRS as
an early prognostic indicator or patient response to
chemotherapy. Magn. Reson. Med., 25, 30-44.
RUIZ-CABELLO, J. & COHEN, J.S. (1992). Phospholipid metabolites
as indicators of cancer cell function. NMR Biomed., 5,
226-233.
SIJENS, P.E., WIJRDEMAN, H.K., MOERLAND, M.A., BAKKER,
C.J.G., VERMEULAEN, J.W.A.H. & LUYTEN, R. (1988). Human
breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T.
Radiology, 169, 615-620.
SHARP, J.C. & LEACH, M.O. (1989). Conformal NMR spectroscopy:
accurate localisation to noncuboidal volumes with optimal
S.N.R. Magn. Reson. Med., 11, 376-388.
SMITH, T.A.D., GLAHOLM, J., LEACH, M.O., MACHIN, L., COLLINS,
D.J. & AYNE, G.S. (1991). A comparison of in vivo and in vitro
31P NMR spectra from human breast tumours: variations in
phospholipid metabolism. Br. J. Cancer, 63, 514-516.
TWELVES, C.J., LOWRY, M., PORTER, D.A., DOBBS, N.A., GRAVES,
P.E., SMITH, M.A. & RICHARDS, M.A. (1993). 31-phosphorus
metabolism of human breast - an in vivo MRS study at 1.5 Tesla.
Br. J. Radiol., 67, 36-45.